Treatment Experiences with CDK4&amp;6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study

Stephenson, Judith J.; Gable, Jonathan E.; Zincavage, Rebekah; Price, Gregory L.; Churchill, Collin; Zhu, Emily; Stenger, Keri; Singhal, Manmohan; Nepal, Bal; Grabner, Michael; Fisch, Michael J.; Debono, David; Geschwender, Amy R; Carter, Gebra Cuyún

doi:10.2147/ppa.s319239

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even if patients with BC describe OAT as convenient to use compared to intravenous chemotherapy [41], the numerous dose adjustments, cycle deferrals or interruptions represent a treatment burden, which may impact patient adherence. To better understand patients' cycle management and avoid any confusion in cycle dates, strategies must be reinforced in daily practice to collect the accurate dates of each cycle start and stop in the electronic medical record, the prescription sheet and on the patient educational written or e-documentation (e.g., "Take one pill per day from 1st January 2022 to 20th January 2022 included, followed by 7 days of treatment break").…”

Section: Patient Empowerment To Self-manage Cdk4/6imentioning

confidence: 99%

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

Bandiera

Locatelli

Courlet

et al. 2023

Cancers

View full text Add to dashboard Cite

The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib is administered orally and cyclically, causing medication adherence challenges. We evaluated components of adherence to palbociclib, its relationship with pharmacokinetics (PK), and drug-induced neutropenia. Patients with metastatic breast cancer (MBC) receiving palbociclib, delivered in electronic monitors (EM), were randomized 1:1 to an intervention and a control group. The intervention was a 12-month interprofessional medication adherence program (IMAP) along with monthly motivational interviews by a pharmacist. Implementation adherence was compared between groups using generalized estimating equation models, in which covariates were included. Model-based palbociclib PK and neutrophil profiles were simulated under real-life implementation scenarios: (1) optimal, (2) 2 doses omitted and caught up at cycle end. At 6 months, implementation was slightly higher and more stable in the intervention (n = 19) than in the control (n = 19) group, 99.2% and 97.3% (Δ1.95%, 95% CI 1.1–2.9%), respectively. The impact of the intervention was larger in patients diagnosed with MBC for >2 years (Δ3.6%, 95% CI 2.1–5.4%), patients who received >4 cycles before inclusion (Δ3.1%, 95% CI 1.7–4.8%) and patients >65 (Δ2.3%, 95% CI 0.8–3.6%). Simulations showed that 25% of patients had neutropenia grade ≥3 during the next cycle in scenario 1 versus 30% in scenario 2. Education and monitoring of patient CDK4/6i cycle management and adherence along with therapeutic drug monitoring can help clinicians improve prescription and decrease toxicity.

show abstract

Section: Patient Empowerment To Self-manage Cdk4/6imentioning

confidence: 99%

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

Bandiera

Locatelli

Courlet

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Mapping the experiences of people with advanced cancer across multiple cancer types—a scoping review

Kalloger

Mitton

et al. 2022

J Cancer Surviv

View full text Add to dashboard Cite

A novel approach for breast cancer treatment: the multifaceted antitumor effects of rMeV-Hu191

Zheng,

Lv,

et al. 2024

Hereditas

View full text Add to dashboard Cite

Background The therapeutic potential of oncolytic measles virotherapy has been demonstrated across various malignancies. However, the effectiveness against human breast cancer (BC) and the underlying mechanisms of the recombinant measles virus vaccine strain Hu191 (rMeV-Hu191) remain unclear. Methods We utilized a range of methods, including cell viability assay, Western blot, flow cytometry, immunofluorescence, SA-β-gal staining, reverse transcription quantitative real-time PCR, transcriptome sequencing, BC xenograft mouse models, and immunohistochemistry to evaluate the antitumor efficacy of rMeV-Hu191 against BC and elucidate the underlying mechanism. Additionally, we employed transcriptomics and gene set enrichment analysis to analyze the lipid metabolism status of BC cells following rMeV-Hu191 infection. Results Our study revealed the multifaceted antitumor effects of rMeV-Hu191 against BC. rMeV-Hu191 induced apoptosis, inhibited proliferation, and promoted senescence in BC cells. Furthermore, rMeV-Hu191 was associated with changes in oxidative stress and lipid homeostasis in infected BC cells. In vivo, studies using a BC xenograft mouse model confirmed a significant reduction in tumor growth following local injection of rMeV-Hu191. Conclusions The findings highlight the potential of rMeV-Hu191 as a promising treatment for BC and provide valuable insights into the mechanisms underlying its oncolytic effect.

show abstract

Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study

Cited by 3 publications

References 32 publications

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study

Mapping the experiences of people with advanced cancer across multiple cancer types—a scoping review

A novel approach for breast cancer treatment: the multifaceted antitumor effects of rMeV-Hu191

Contact Info

Product

Resources

About